Cardinal Health reported substantially higher profitability with operating income roughly doubling year-over-year, while simultaneously experiencing a significant decline in operating cash flow generation.
The dramatic improvement in reported profitability contrasts sharply with weakened cash generation, creating questions about earnings quality and the sustainability of the profit expansion. This divergence between income statement performance and cash flow metrics warrants careful scrutiny from investors, particularly given the company's historically stable financial profile as an established healthcare distributor.
Cardinal Health delivered substantially higher profitability with both net income and operating income roughly doubling, while gross profit grew a more modest 10.2%. However, this earnings improvement was accompanied by a concerning 36% decline in operating cash flow to $2.4B and reduced cash balances. The company's balance sheet expanded with total assets growing 18% and inventory increasing 12.5%, while the negative stockholders' equity position improved slightly but remains a structural concern.
Net income grew 83.2% — bottom-line growth signals improving overall business health.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
Operating cash flow fell 36.3% — earnings quality concerns; investigate working capital changes and non-cash items.
Cash decreased 24.5% — monitor burn rate and upcoming capital needs.
Asset base grew 17.7% — expansion through organic growth, acquisitions, or capital deployment.
Debt rose 17.5% — additional borrowing for investment or operations; monitor coverage ratios.
Equity base grew 13.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Inventory built 12.5% — monitor whether demand supports this build or if write-downs may follow.
Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →